Highlighting immunotherapy research from 2016, a white paper from the Institute for Clinical Immuno-Oncology founded by the Association of Community Cancer Centers isolated emerging policy issues and challenges that may impact the future of immune-oncology in practice.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
